NCT06112340View on ClinicalTrials.gov

Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)

PHASE2/PHASE3RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

October 11, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Thyroid Eye DiseaseGraves OrbitopathyEndocrine System DiseasesEye DiseasesThyroid Associated OphthalmopathyGraves OphthalmopathyThyroid DiseasesOrbital DiseasesProptosisIGF1RExophthalmosHashimoto

Interventions

DRUG

linsitinib

Study medication taken twice daily by mouth

Trial Locations (2)

26506

RECRUITING

West Virginia University Eye Institute, Morgantown

33136

RECRUITING

Bascom Palmer Eye Institute, Miami

All Listed Sponsors

lead

Sling Therapeutics, Inc.

INDUSTRY